CABLIVI: payments to doctors
Payments that named CABLIVI as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $1.8M
- Providers
- 4,823
- Transactions
- 9,726
- Average per transaction
- $189
The per-transaction average — $189 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 4,823 providers the average total is $380, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Sanofi | $1,791,580 | 97.7% |
| Sanofi-aventis U.S. LLC | $37,578 | 2.0% |
| Bioverativ Therapeutics Inc. | $3,105 | 0.2% |
| Sanofi US Services Inc. | $1,873 | 0.1% |